Most Read Articles
Roshini Claire Anthony, 14 Dec 2016

The addition of ibandronate to adjuvant hormonal therapy provides no benefit to postmenopausal women with HR-positive breast cancer, according to early results from the phase III TEAM IIB trial (BOOG 2006-4)*.

Metaraminol trumps ephedrine for elective caesarean

21 Jul 2019

Metaraminol may be a better vasopressor than ephedrine for mothers undergoing elective caesarean section, a recent meta-analysis has found.

Accessing the databases of PubMed, Embase and the Cochrane Library, researchers retrieved four randomized controlled trials that compared metaraminol with other vasopressors for spinal anaesthesia during caesarean delivery. The cumulative sample included 409 participants.

Relative to ephedrine, metaraminol resulted in a higher mean umbilical arterial pH (standardized mean difference [SMD], 0.82, 95 percent CI, 0.01–1.62; p=0.05) and a lower incidence of arterial pH <7.2 (risk ratio [RR], 0.08, 0.01–0.63; p=0.02). Nauseous vomiting was also significantly lower in those treated with metaraminol (RR, 0.16, 0.04–0.57; p=0.005).

In contrast, both vasopressors yielded comparable incidence rates of Apgar scores <7 at 1 minute (RR, 0.62, 0.08–4.85; p=0.65), hypotension (RR, 0.56, 0.26–1.17; p=0.12) and hypertension (RR, 1.44, 0.82–2.54; p=0.20).

When compared with phenylephrine, metaraminol resulted in a higher mean umbilical arterial pH (SMD, 0.42, 0.15–0.68; p=0.002) and incidence rate of hypertension (RR, 1.80, 1.32–2.46; p=0.0002).

No differences were observed for the incidence rate of umbilical pH <7.2 (RR, 0.18, 0.02–1.48; p=0.11), Apgar scores <7 at 1 minute (RR, 0.40, 0.11–1.45; p=0.16), hypotension (RR, 0.80, 0.53–1.22; p=0.30), or nausea or vomiting (RR, 0.53, 0.16–1.73; p=0.29).

Overall, prophylactic metaraminol appears to be superior to ephedrine for elective caesarean section delivery, while being at least not inferior to phenylephrine, said researchers. There is a need for further studies to facilitate the selection of the optimal vasopressor.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 14 Dec 2016

The addition of ibandronate to adjuvant hormonal therapy provides no benefit to postmenopausal women with HR-positive breast cancer, according to early results from the phase III TEAM IIB trial (BOOG 2006-4)*.